Merck says tulisokibart hits primary endpoint in Phase 2b hidradenitis suppurativa trial

By Public Technologies
  • Merck disclosed first Phase 2b results for tulisokibart in moderate-to-severe hidradenitis suppurativa, slated for presentation at EADV 2026.
  • The trial met the main efficacy goal, showing patients on higher-dose regimens were more likely to improve than on placebo.
  • Key secondary measures also trended in favor of treatment, including deeper clinical responses and better patient-reported quality of life.
  • Safety looked broadly comparable with placebo, with serious adverse events uncommon and no serious or opportunistic infections reported.
  • Merck plans to move the drug into Phase 3 in hidradenitis suppurativa, expanding its anti-TL1A program beyond inflammatory bowel disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609300815BIZWIRE_USPR_____20260930_BW948161) on September 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.